Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Receptos begins enrollment of Phase 3 trial of RPC1063 in relapsing multiple sclerosis
A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta.
Sublime Microglia: Expanding Roles for the Guardians of the CNS.
Magnetic Resonance Phase Alterations in Multiple Sclerosis Patients with Short and Long Disease Duration.
Solodyn
The unwavering commitment of regulatory T cells in the suppression of autoimmune encephalomyelitis: Another aspect of immune privilege in the CNS.
Age-dependent effects on the treatment response of natalizumab in MS patients.
Psychotherapeutic and psychosocial interventions for managing stress in multiple sclerosis: the contribution of mindfulness-based interventions.
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010.
Reduced expression of PGC-1α partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex.
Nav1.5 sodium channels in macrophages in multiple sclerosis lesions.
Does glatiramer acetate provoke hepatitis in multiple sclerosis?
Disability weight for each level of the Expanded Disability Status Scale in multiple sclerosis.
Rush University Medical Center Sells AMPYRA® Royalty Rights to DRI Capital Managed Fund for Approximately $42 Million
Patient Perspectives and Experience with Dalfampridine Treatment in Multiple Sclerosis-Related Walking Impairment: The Step Together Program.
Simvastatin shows promise in treating progressive multiple sclerosis, study finds.
Atypical guillain-barré syndrome misdiagnosed as lumbar spinal stenosis.
Separated at birth? The functional and molecular divergence of OLIG1 and OLIG2.
Natalizumab in the treatment of rheumatoid arthritis in subjects receiving methotrexate
Twin studies and the heritability of MS: a conclusion.
The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: Lessons from gene expression signatures.
QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients.
MS related employment and disease modifying treatment in the German working population: 1994-2009.
Multiple sclerosis treatment: current best practice.
Sexual dysfunction ın multiple sclerosis: Gender differences.

Pages